Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Priothera Limited
The Irish biotech has launched a Phase IIb/III trial of its sphingosine 1 phosphate receptor modulator mocravimod, expanding a mode of action that has been successful in autoimmune indications into the hematology space.
At a time when the sector has fallen out of favor with venture capitalists and public markets, Irish biotech Priothera is accessing funds from the EU to advance a Phase IIb/III study of mocravimod for acute myeloid leukemia patients receiving hematopoietic stem cell transplants.
VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.
The Dublin-based venture capital group will be looking to replicate the success of portfolio companies Inflazome and KaNDy, recently acquired by Roche and Bayer respectively, with the biotechs backed from its latest fund.
- Gene Therapy, Cell Therapy
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.